Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
MEX:RPRX: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany IPO Date
2020-09-17Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.23 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.11 | |||||
| Debt-to-EBITDA | 3.96 | |||||
| Interest Coverage | 7.46 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.6 | |||||
| Beneish M-Score | -3.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.6 | |||||
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.7 | |||||
| 3-Year FCF Growth Rate | -2.9 | |||||
| 3-Year Book Growth Rate | 5.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.63 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.67 | |||||
| 9-Day RSI | 37.14 | |||||
| 14-Day RSI | 39.66 | |||||
| 3-1 Month Momentum % | -1.75 | |||||
| 6-1 Month Momentum % | 3.9 | |||||
| 12-1 Month Momentum % | 6.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 1.54 | |||||
| Cash Ratio | 1.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.98 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 38.7 | |||||
| Forward Dividend Yield % | 3.22 | |||||
| 5-Year Yield-on-Cost % | 2.98 | |||||
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | 3.38 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 68.13 | |||||
| Net Margin % | 50.53 | |||||
| FCF Margin % | 123.59 | |||||
| ROE % | 17.61 | |||||
| ROA % | 6.81 | |||||
| ROIC % | 10.12 | |||||
| 3-Year ROIIC % | -9.47 | |||||
| ROCE % | 11.68 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.89 | |||||
| Forward PE Ratio | 5.99 | |||||
| PE Ratio without NRI | 12.87 | |||||
| PS Ratio | 6.63 | |||||
| PB Ratio | 1.64 | |||||
| Price-to-Tangible-Book | 1.64 | |||||
| Price-to-Free-Cash-Flow | 5.37 | |||||
| Price-to-Operating-Cash-Flow | 5.37 | |||||
| EV-to-EBIT | 8.81 | |||||
| EV-to-Forward-EBIT | 8.16 | |||||
| EV-to-EBITDA | 8.81 | |||||
| EV-to-Forward-EBITDA | 8.16 | |||||
| EV-to-Revenue | 7.47 | |||||
| EV-to-Forward-Revenue | 6.39 | |||||
| EV-to-FCF | 6.09 | |||||
| Price-to-GF-Value | 0.73 | |||||
| Price-to-Graham-Number | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 11.35 | |||||
| FCF Yield % | 25.29 | |||||
| Forward Rate of Return (Yacktman) % | -14.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 40,613.804 | ||
| EPS (TTM) (MXN) | 46.977 | ||
| Beta | -0.27 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 23.16 | ||
| 14-Day RSI | 39.66 | ||
| 14-Day ATR (MXN) | 1.019296 | ||
| 20-Day SMA (MXN) | 528.5 | ||
| 12-1 Month Momentum % | 6.28 | ||
| 52-Week Range (MXN) | 448.33 - 586 | ||
| Shares Outstanding (Mil) | 444.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Royalty Pharma PLC Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(MEX:RPRX)'s stock price today?
The current price of MEX:RPRX is MXN528.50. The 52 week high of MEX:RPRX is MXN586.00 and 52 week low is MXN448.33.
When is next earnings date of Royalty Pharma PLC(MEX:RPRX)?
The next earnings date of Royalty Pharma PLC(MEX:RPRX) is 2025-02-14 Est..
Does Royalty Pharma PLC(MEX:RPRX) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(MEX:RPRX) is 2.98% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(MEX:RPRX) was 0.55. The lowest was 0.33. And the median was 0.41. The  Forward Dividend Yield % of Royalty Pharma PLC(MEX:RPRX) is 3.22%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers